Positive Data at AAO Show Utility, Versatility of Clearside Suprachoroidal Space Platform

  Favorable Safety Profiles and Encouraging Efficacy Data Reported in Clinical Trials in the Suprachoroidal Space (SCS^®) Across Multiple Therapeutic Areas using Clearside’s SCS Microinjector^® -

- SCS Microinjector^® Featured in Multiple Oral and Poster Presentations at Recent American Academy of Ophthalmology (AAO) 2022 Annual Meeting -

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that clinical data from multiple internal and partnered programs were presented at the recent 2022 Annual Meeting of the American Academy of Ophthalmology (AAO), the world's largest association of eye physicians and surgeons.

https://www.biospace.com/article/releases/positive-data-presentations-at-aao-annual-meeting-demonstrate-utility-and-versatility-of-clearside-biomedical-s-proprietary-suprachoroidal-space-platform/